Abstract: A method of determining sensitivity to cancer treatment includes the step of determining the presence of overexpression of MYC in a biological sample from a patient suffering from cancer, wherein the presence of overexpression of MYC indicates a sensitivity to a treatment by a CDK9 inhibitor and wherein the cancer is selected from the group consisting of carcinoma, leukemia, and lymphoma.
Type:
Application
Filed:
August 19, 2019
Publication date:
February 20, 2020
Inventors:
Scott William LOWE, Charles J. SHERR, Chun-Hao HUANG, Amaia LUJAMBIO
Abstract: The present invention provides a method of providing adjuvant treatment to a human patient which comprises administering to such a patient therapeutically effective doses of dabrafenib and trametinib for a time period sufficient to increase relapse-free survival (RFS).
Abstract: Combination therapies for treatment of cancer are provided. The disclosed methods comprise administration of a cyclin-dependent kinase inhibitor and a DNA methyltransferase inhibitor to a mammal in need thereof.
Type:
Application
Filed:
October 28, 2019
Publication date:
February 20, 2020
Inventors:
David J. Bearss, Steven L. Warner, Adam Siddiqui-Jain, Clifford J. Whatcott, Wontak Kim
Abstract: The present invention provides small molecule inhibitors of BMP signaling that are useful for treating diseases or conditions associated with BMP signaling, including cancers of the central nervous system.
Type:
Application
Filed:
January 18, 2018
Publication date:
February 20, 2020
Inventors:
Corey R. Hopkins, Charles C. Hong, Craig W. Lindsley, Darren W. Engers
Abstract: Described herein are compounds of Formula (I) or Formula (VI), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I) or Formula (VI) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions thereof for treating diseases are also provided.
Type:
Application
Filed:
July 25, 2019
Publication date:
February 20, 2020
Inventors:
Winston Zapanta Ong, Pawel Wojciech Nowak, Ben C. Askew, Jinsoo Kim
Abstract: In one aspect, the invention provides compounds of Formula I, and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease, diabetes, bone loss, and cancer, using a compound of Formula I.
Type:
Application
Filed:
August 13, 2019
Publication date:
February 20, 2020
Inventors:
Debra ELLIES, F. Scott Kimball, Robert N. Young
Abstract: The present invention provides aphenothiazine derivative for use in preventing and/or treating infectious purpura or purpura fulminans, wherein infection is caused by a bacterium. The present invention further relates to a composition for the use in preventing and/or treating infectious purpura or purpura fulminans comprising a phenothiazine derivative and an antibiotic selected in the group consisting of beta-lactams, aminoglycosides or dexamethasone.
Type:
Application
Filed:
November 6, 2017
Publication date:
February 20, 2020
Applicants:
Centre National de la Recherche Scientifique (CNRS), Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Descartes
Inventors:
Sandrine Bourdoulous, Kévin Denis, Loïc Le Guennec
Abstract: The present invention relates to the use of ruthenium(II) complexes for preparing a medicinal product for treating cancer, particularly cancer comprising cancer stem cells. Said ruthenium complexes are capable of selectively metallating guanine quadruplexes, thus resulting in increased expression of the c-MYC oncogene. This increase in the proportion of c-MYC may promote the differentiation of cancer stem cells.
Type:
Application
Filed:
November 10, 2017
Publication date:
February 20, 2020
Inventors:
Jessica RODRÍGUEZ VILLAR, José Luis MASCAREÑAS CID, José RODRÍGUEZ COUCEIRO, Jesús MOSQUERA MOSQUERA, Marcos Eugenio VÁZQUEZ SENTÍS, Bruno SAINZ ANDING
Abstract: Methods of treating a testosterone deficiency or its symptoms with a pharmaceutical formulation of testosterone esters are provided. The methods are designed to provide optimum serum testosterone levels over an extended period.
Type:
Application
Filed:
March 21, 2019
Publication date:
February 20, 2020
Inventors:
Robert E. DUDLEY, Panayiotis P. CONSTANTINIDES, James A. LONGSTRETH
Abstract: The present invention relates to skeletal muscle hypertrophy inducers as well as their uses to promote skeletal muscle regeneration, to prevent skeletal muscle atrophy, or in the treatment or prevention of a disease or injury resulting in loss of skeletal muscle tissue and/or muscle weakness. It further relates to the non-therapeutic use of such compounds to increase muscle mass, muscle strength and/or muscle performance in a subject.
Abstract: The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
Type:
Application
Filed:
October 9, 2019
Publication date:
February 20, 2020
Inventors:
Richard Gail Lancaster, Kay K. Olmstead, Masashi Kagihiro, Mitsuhiro Matono, Ikuko Taoka, Mark Pruzanski, David Shapiro, Roya Hooshmand-Rad, Richard Pencek, Cathi Sciacca, Lise Eliot, Jeffrey Edwards, Leigh A. MacConell, Tonya K. Marmon
Abstract: Expression of a phosphatase inhibitor in heart cells can be used to treat cardiac disorders, e.g., heart failure. Decreasing phosphatase activity can improve ?-adrenergic responsiveness.
Type:
Application
Filed:
April 11, 2019
Publication date:
February 20, 2020
Inventors:
Roger J. Hajjar, Federica Del Monte, Evangelia Kranias
Abstract: The present invention relates to AceFaPC (1-Acetyl-2-Fatty acyl-glyceroPhosphoCholine) for use in the prevention and treatment of diseases associated with an acetylcholine deficiency. The invention also relates to the AceFaPC molecule in which Fa represents an unsaturated acyl comprising at least 14 carbon atoms, and the pharmaceutical compositions comprising same.
Type:
Application
Filed:
March 8, 2018
Publication date:
February 20, 2020
Inventors:
Michel LAGARDE, Evelyne VERICEL, Madeleine PICQ, Michel GUICHARDANT, Nathalie BERNOUD-HUBAC, Baptiste FOURMAUX
Abstract: Disclosed are combination therapies including administration of Caspase-1 dependent anticancer agents and PGE2 antagonists, and the use of such therapies in the treatment of cell proliferative diseases.
Type:
Application
Filed:
April 6, 2018
Publication date:
February 20, 2020
Inventors:
William W. Bachovchin, Hung-sen Lai, Wengen Wu
Abstract: The named inventors claim discovery of synergistic anti-cancer effects of combinations of one or more sea cucumber glycosides such as Frondoside A or other sea cucumber glycosides and Andrographolide or an Andrographolide analog, wherein the biological effects are may be more beneficial than the single components making up the said invention. The inventors claim new methods and compositions of matter to treat cancer in mammals, and additionally a method to effectively treat cancer stem cells in mammals, with a composition comprised of one or more sea cucumber glycosides and Andrographolide, or an andrographolide analog.
Type:
Application
Filed:
August 20, 2018
Publication date:
February 20, 2020
Inventors:
Thomas E Adrian, Peter D Collin, Robert A Newman
Abstract: The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.
Abstract: The present invention relates to an extended release capsules comprising multiple units of Capecitabine, wherein the dissolution of Capecitabine from the said composition is extended up to 12 hours. Further the present invention discloses process for the preparation of the said composition.
Abstract: Provided herein are methods and compositions for modulating T-cell activity by altering DNA methylation status. Altering the methylation status of CD8+ T cells can prevent T-cell exhaustion and maintain effector functions during sustained antigen exposure. The methods and compositions can be used to treat symptoms of chronic infections and cancer. Further, the methods and compositions relate to predicting T-cell activity by measuring the methylation status of specific memory cell methylation markers and using the markers to identify and separate populations of CD8 T cell having desired T cell activity. The memory cell methylation markers can further be used to identify subjects with chronic infections or cancer that would benefit from personalized therapy, including immune checkpoint blockade therapy.
Type:
Application
Filed:
December 7, 2017
Publication date:
February 20, 2020
Applicant:
St. Jude Children's Research Hospital
Inventors:
Benjamin Youngblood, Hossam Abdelsamed, Hazem Ghoneim
Abstract: Multitargeted pyrimidine nucleoside carbamates, substituted with fluorine at both the base and the sugar moieties, are disclosed (see Formula I): where R=linear or branched alkyl (C1-7); R?=H, hydroxy protecting group; R?=H, phosphate ester, amino acid alkyl (C1-7) ester phoshoramidate, or phosphorodiamidate. The disclosed compounds are fluoropyrimidine prodrugs that are characterized by a novel combination of structural components that provide intracellular metabolites capable of 1) inhibiting several cellular enzymes required for the synthesis and proper functioning of DNA, and 2) causing DNA damage by misincorporation into DNA. By acting on multiple targets with different mechanisms of action, compounds of Formula I reduce the likelihood of the emergence of drug resistance, a major drawback of the use of nucleoside-based anticancer and antiviral drugs.
Abstract: The present invention is directed to the use of cangrelor for the treatment and/or prevention of shunt thrombosis in patients suffering congenital heart diseases undergoing shunt surgery. The invention is also directed to the use of cangrelor for the treatment and/or prevention of stent thrombosis in pediatric patients undergoing stent implantation.
Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.
Type:
Application
Filed:
August 30, 2019
Publication date:
February 20, 2020
Inventors:
Sudhir AGRAWAL, Daqing WANG, Wayne JIANG
Abstract: The invention relates to the fields of pharmacology, and provides metabolic supplement formulations and methods for the treatment of depression and anxiety. The metabolic supplement formulation comprises a combination of a vitamin B6 compound, a vitamin B12 compound, a folate, a betaine, N-acetyl-L-tyrosine, and a pharmaceutically acceptable carrier.
Abstract: A method of attenuating, treating or preventing cognitive aging in an individual who does not have dementia includes administering to the individual a therapeutically effective amount of a composition containing an omega-3 fatty acid, a nitric oxide releasing compound, Vitamin B12 and choline. The composition is administered in a daily dose that provides 0.1 to 50 times the recommended daily requirement (RDA) of Vitamin B12 per day, more preferably 0.1 to 40 times the recommended daily requirement (RDA) of Vitamin B12 per day and 0.01 to 10.0 times the recommended daily requirement (RDA) of choline. Optionally Vitamin B6 and/or Vitamin B9 can be included in the composition. The method can achieve a benefit that is one or more of decreasing brain atrophy, increasing or maintaining number of synapses, increasing amyloid-? phagocytosis, or decreasing or maintaining neuro inflammation in the non-demented individual. The method can prevent dementia in an individual at risk thereof, for example an elderly human.
Type:
Application
Filed:
April 5, 2018
Publication date:
February 20, 2020
Inventors:
Claus Rieker, Julie Laure Hudry-Labbe, Jeroen Antonius Johannes Schmitt, Corina Boschat
Abstract: In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for treating or ameliorating a cancer by inhibiting expression or activity of Mouse Double Minute 2 homolog (MDM2), an APOBEC3G (A3G) protein, message (mRNA) or gene, and/or an ADAR1p150 protein, message (mRNA) or gene, e.g., by increasing the presence of in a cell or adding to a cell a molecule inhibitory to MDM2, APOBEC3G and/or ADAR1p150 expression, such as an miRNA that binds to MDM2, APOBEC3G and/or ADAR1p150 transcripts, or any molecule that can inhibit or destabilize the transcripts, resulting in decreased MDM2, APOBEC3G and/or ADAR1p150 expression, to treat a cancer such as leukemia, e.g., by inhibiting the propagation of a cancer cell, a leukemia cell, a leukemia stem cell (LSC) or a pre-leukemia cell stem cell (pre-LSC).
Type:
Application
Filed:
August 16, 2019
Publication date:
February 20, 2020
Inventors:
Catriona JAMIESON, Raymond DIEP, Jane ISQUITH, Qingfei JIANG, Jessica PHAM
Abstract: The present invention relates to a periodontal gel composition, more particularly to a liquid composition having a low viscosity at ambient temperature, which upon warming to body temperature solidifies into a viscous gel and then releases a therapeutic agent, e.g., an antibacterial agent, in a sustained release manner; and to a method of use.
Type:
Application
Filed:
February 27, 2018
Publication date:
February 20, 2020
Inventors:
Keren Mevorat Kaplan, Dadi Segal, Danny Rosenbaum, Igal Liapis, Igor Makarovsky, Meir Stern
Abstract: The present invention relates generally to agents and medicinal protocols useful in the prophylaxis and/or treatment of respiratory diseases or conditions such as asthma, allergic rhinitis and chronic obstructive pulmonary disease (COPD). More particularly, the present invention relates to the use of a sulfated xylan or a derivative or homolog thereof in the treatment of respiratory diseases or conditions.
Abstract: Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain nonabsorbable compositions and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons, the conjugate base of a strong acid and/or a strong acid from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.
Type:
Application
Filed:
May 5, 2017
Publication date:
February 20, 2020
Inventors:
Gerrit KLAERNER, Eric F. CONNOR, Randi K. GBUR, Matthew J. KADE, Paul H. KIERSTEAD, Jerry M. BUYSSE, Michael J. COPE, Kalpesh N. BIYANI, Son H. NGUYEN, Scott M. TABAKMAN
Abstract: The use of a composition which comprises lignosulfonate and is substantially free of elemental sulphur for the prevention and treatment of pathogenic and medical disorders in humans and animals. In some embodiments the lignosulfonate is radically polymerized. In some embodiments the composition is formulated as an animal feed additive or supplement. The disclosure also encompasses a method of preventing or treating a pathogenic or medical disorder in a human or animal subject by administering the composition to the subject in an effective dose to attenuate the pathogenic effect of a pathogen or other biological agent, thereby enabling the subject to mount an effective immune response to the pathogen or other biological agent.
Abstract: Disclosed are compositions of matter, treatment methods, and combination therapies for addressing panic attacks in patients suffering from Panic Disorder (PD). In one embodiment the invention provides the use of Noble Gas containing mixtures at a sufficient concentration and frequency to prevent, and/or inhibit frequency of panic attacks. In one particular embodiment xenon gas is administered by inhalation of xenon-oxygen mixtures at concentrations ranging from 15%/85% to 30%/70% with xenon consumption is capped at 3.0 liters per procedure. In other embodiments xenon-oxygen or xenon-oxygen-nitrogen mixtures are administered at sub-anesthetic concentrations which are sufficient to elicit reduction in panic attacks and/or synergize with medications patients are receiving for panic/anxiety symptoms.
Abstract: The present invention relates to compositions and their use for oral care. In particular, the compositions and methods are for maintaining oral health and/or treating various oral conditions such as gingivitis. The present invention relates to methods and uses of stabilized amorphous calcium phosphate (ACP) and/or stabilized amorphous calcium fluoride phosphate (ACFP) in the preparation of a medicament for reducing pathogenic oral bacteria at an oral site in an individual; increasing commensal oral bacteria at an oral site in an individual; decreasing the proportion of pathogenic oral bacteria at an oral site in an individual; inhibiting oral dysbiosis; reducing gingival inflammation in an individual in need thereof; treating gingivitis in an individual in need thereof; and treating chronic gingivitis in an individual in need thereof.
Abstract: Provided are methods of treatment involving immunotherapy, such as T cell therapy, and administration of a tryptophan metabolism and/or kynurenine pathway modulator. In some embodiments, the method includes a combination therapy that involves administration of engineered T cells, such as chimeric antigen receptor (CAR)-expressing cells, and a tryptophan metabolism and/or kynurenine pathway modulator, such as an inhibitor of an enzyme. Also provided are engineered cells in which the expression of a molecule involved in the kynurenine pathway is modified. Also provided are methods of manufacturing engineered cells, cells, compositions, methods of administration to subjects, nucleic acids and kits for use in the methods. In some aspects, features of the methods and cells provide for increased or improved activity, activity, outcome, function, response, persistence, expansion and/or proliferation of cells for adoptive cell therapy.
Type:
Application
Filed:
October 13, 2017
Publication date:
February 20, 2020
Applicant:
Juno Therapeutics, Inc.
Inventors:
Michael PORTS, Evan Paul THOMAS, Hyam I. LEVITSKY
Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
Abstract: Disclosed herein are methods of gene editing, or endogenous suppression, of cytokines/chemokines/transcription factors secreted from chimeric antigen receptor (CAR)-bearing immune effector cell such as CAR-T cells for the mitigation of cytokine release syndrome and/or CAR-T associated neuropathy. These methods involve insertion of the CAR into a locus of a cytokine gene, blocking its expression. Also disclosed herein are (CAR)-bearing immune effector cells with CARs inserted into a locus of a cytokine gene, and methods of treatment of diseases with immunotherapy with a reduced incidence of cytokine release syndrome and/or CAR-T associated neuropathy.
Type:
Application
Filed:
May 31, 2019
Publication date:
February 20, 2020
Inventors:
John DiPersio, Matthew Cooper, Alun Carter
Abstract: A drug delivery platform providing flexible fine tune of cell therapy is disclosed herein. Particularly, an engineered fusion protein is coupled with a high affinity ligand carrying at least one payload of drug to be internalized by the transplanted cell to observe or regulate transplanted cell therapy effects.
Type:
Application
Filed:
February 17, 2018
Publication date:
February 20, 2020
Inventors:
Philip S. LOW, Madduri SRINIVASARAO, Boning ZHANG
Abstract: The present disclosure relates to methods and products for preventing and/or treating cancer, and in particular to methods, cells and products for preventing and/or treating cancer using adoptive immunotherapies. In certain embodiments, the present disclosure provides a method of treating a subject suffering from, or susceptible to, a cancer associated with chemokine expressing cells, the method comprising exposing the subject to T cells expressing a receptor to the chemokine and thereby treating the subject.
Abstract: The technology relates in part to compositions and methods for inducing an immune response against the Preferentially Expressed Antigen of Melanoma (PRAME). Provided are methods for treating hyperproliferative diseases by inducing an immune response against PRAME antigen; the immune response may be induced by specifically targeting PRAME-expressing cells using T cell receptors directed against PRAME.
Type:
Application
Filed:
July 24, 2019
Publication date:
February 20, 2020
Inventors:
Mirjam H.M. Heemskerk, J.H. Frederik Falkenburg
Abstract: The present invention includes compositions and methods for modifying primary T cells. In one aspect, the invention comprises administering to a cell a stem-loop Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) RNA (st-crRNA) and a Cpf1 enzyme.
Abstract: Provided are methods for administering multiple doses of cells, such as T cells, to subjects for cell therapy. Also provided are compositions and articles of manufacture for use in the methods. The cells generally express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). The methods generally involve administering a first and at least one consecutive dose of the cells. Timing of the doses relative to one another, and/or size of the doses, in some embodiments provide various advantages such as lower or reduced toxicity and improved efficacy, for example, due to increased exposure of the subject to the administered cells. In some embodiments, the first dose is a relatively low dose, such as one that reduces tumor or disease burden, thereby improving the efficacy of consecutive or subsequent doses, and the consecutive dose is a consolidating dose.
Abstract: Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reducing resistance to the treatment, prevention, and diagnosis of a condition/disease associated with insufficient quantity and/or quality of hematopoietic stem cells (HSCs) and differentiated blood cells thereof. Embodiments include compositions and methods for treating the condition/disease, comprising the step of providing to a subject at least one therapeutically effective dose of a composition disclosed herein. Other embodiments include methods for generating and/or collecting hematopoietic stem cells from a subject.
Type:
Application
Filed:
June 15, 2018
Publication date:
February 20, 2020
Applicant:
Indiana University Research and Technology Corporation
Inventors:
Hal Edward Broxmeyer, Maegan Lynn Capitano, Scott Harrison Cooper, Qingchun Cai
Abstract: The present invention provides methods and compositions for generation of mitochondria replaced cells (MirC), and therapeutic methods for using such compositions for treating a subject having an age-related disease or syndrome, mitochondrial disease or disorder, or otherwise in need of mitochondrial replacement. Also provided are methods and compositions for producing a recipient cell having a mitochondrial disease or disorder, as well as methods and compositions for producing or enhancing production of an inducible pluripotent stem cell (iPSC). In addition, methods and compositions to enhance mitochondrial transfer are also included.
Abstract: We describe the use of exosome such as mesenchymal stem cell exosomes in a method of promoting, restoring or enhancing homeostasis in an individual suffering from graft versus host disease (GVHD) or epidermolysis bullosa (EB). The homeostasis may comprise immune homeostasis such as maintenance of an immune response. The method may comprise administering a therapeutically effective amount of exosome to the individual.
Type:
Application
Filed:
October 23, 2019
Publication date:
February 20, 2020
Applicant:
Agency for Science, Technology and Research (A*STAR)
Abstract: Embodiments of the invention relate to human, non-mesenchymal c-kit positive lung stem cells negative for the CD44, CD73 and CD105 markers of the mesenchymal stromal cell lineage (non-mhLSCs) and their therapeutic use in the treatment and/or prevention of lung diseases or disorders. Provided herein are compositions comprising non-mhLSCs and methods of preparing and using non-mhLSCs for the treatment and/or prevention of lung diseases or disorders.
Abstract: A tissue construct is provided that comprises a pancreas derived microvessel fragment and a pancreatic islet cell. The pancreas derived microvessel fragment and the pancreatic islet cell can be incorporated into a biocompatible medium. Tissue constructs can be comprised of other cells, such as stem cells, combined with the pancreas derived microvascular fragment. Methods for isolating microvessel fragments from a pancreas are also provided and include enzymatic digestion of pancreatic tissue and separation of microvessel fragments from endocrine and exocrine tissue. Methods for treating diabetes are further provided and include administration of the tissue constructs.
Type:
Application
Filed:
April 27, 2018
Publication date:
February 20, 2020
Inventors:
Balamurugan APPAKALAI, Stuart K. WILLIAMS
Abstract: The present invention relates to a method of treating acute or chronic systemic graft-versus-host disease (GVHD) with extracellular vesicles, e.g., exosomes obtained from human cardiospheres or cardiosphere-derived cells (CDCs), wherein systemic GVHD involves, e.g., at least two organs selected from the group consisting of the skin, mucosa, gastrointestinal tract, liver, lungs, joints and fascia, genitalia, and eyes. The present invention also provides a pharmaceutical formulation comprising extracellular vesicles, e.g., exosomes obtained from human cardiospheres or CDCs, for systemic administration, e.g., intravenous infusion, to a human subject in need of treatment of systemic GVHD.
Type:
Application
Filed:
May 4, 2018
Publication date:
February 20, 2020
Inventors:
Luis RODRIGUEZ-BORLADO, Houman HEMMATI, Kiel A. PECK, Linda MARBAN, Jennifer J. MOSELEY
Abstract: The invention provides compositions based on either medicinal honey containing broad spectrum antibacterial activities of peroxide, polyphenols and methylglyoxal, or an effective amount of an active anti-inflammatory ingredient of mineral solids fortified with methylglyoxal antibacterial activity, or a mixture of both for the treatment of wounds; and methods of treating a wound, comprising contacting a wound with any one of the above compositions or a wound dressing containing any one of the above compositions.
Abstract: This invention teaches systems and methods for identifying, targeting and destroying cancer cells domesticated organism such as a pet or zoo animal. As cells progress from a normal to a cancerous state their accelerated metabolic rates and adapted pathways generate a higher heat signature that serves as a targeting beacon for a specialized cell killing vector. Suitable vectors include modified or adapted viruses, modified or adapted intracellular bacteria and/or engineered liposomes. Especially preferred is the bacterial vector because of its ease of production. The bacterial vector is selectively targeted to recognize cells whose temperature is slightly elevated and ambient pH suppressed due to cancer related alterations to metabolism. An additional targeting feature, such as recognition of the MCT4 transmembrane protein exaggeratively expressed on the cancer cell outer membrane, may provide additional targeting specificity.
Abstract: Compositions and methods for treating cancer are provided. In particular, the compositions comprise an anti-neoplastic agent and either an interferon type I agonist or an interferon type II agonist, or a combination of an interferon type I agonist and an interferon type II agonist.
Type:
Application
Filed:
July 22, 2019
Publication date:
February 20, 2020
Applicant:
EnGeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu BRAHMBHATT, Jennifer MacDiarmid